• 1. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 2. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 3. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 4. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers

Market Research and Analysis Report on 3-Methyl-4-Trifluoromethoxyphenylboronic Acid (CAS No. 871362-79-7)

The compound 3-Methyl-4-Trifluoromethoxyphenylboronic Acid, identified by the CAS number 871362-79-7, has emerged as a significant player in the field of chemical biology and drug discovery. This boronic acid derivative is widely utilized in Suzuki-Miyaura coupling reactions, a cornerstone of modern organic synthesis, enabling the construction of complex aromatic systems with high precision.

Recent advancements in medicinal chemistry have highlighted the importance of trifluoromethoxy groups in modulating pharmacokinetic properties, such as metabolic stability and bioavailability. The presence of this group in 3-Methyl-4-Trifluoromethoxyphenylboronic Acid makes it an attractive building block for the development of novel therapeutic agents targeting various disease states, including cancer, inflammation, and central nervous system disorders.

The global market for specialty chemicals, particularly those employed in drug discovery and development, has witnessed steady growth driven by increasing investments in pharmaceutical R&D. The demand for high-quality boronic acids like 3-Methyl-4-Trifluoromethoxyphenylboronic Acid is further bolstered by the rise of continuous-flow chemistry and automation in synthetic processes, which enhance efficiency and scalability.

From a supply chain perspective, key players in the chemical manufacturing sector are actively optimizing production strategies to meet the surging demand for this compound. Strategic partnerships between research institutions and industry leaders are fostering innovation, ensuring a steady supply of this critical intermediate while maintaining adherence to stringent quality control standards.

In conclusion, 3-Methyl-4-Trifluoromethoxyphenylboronic Acid (CAS No. 871362-79-7) occupies a pivotal position in the contemporary landscape of chemical biology and drug development. Its unique chemical properties and versatility in synthetic applications position it as a valuable asset for researchers and manufacturers alike, contributing to the advancement of novel therapeutics and chemical entities.

• 958451-75-7( )
• 958451-74-6([3-(difluoromethoxy)-4-methylphenyl]boronic acid)
• 850033-39-5(2-Methyl-4-trifluoromethoxyphenylboronic Acid)
• 1072946-64-5(5-Cyano-2-(trifluoromethoxy)phenylboronic Acid)
• 958451-72-4(4-Difluoromethoxy-3-methyl-benzeneboronic acid)
• 149507-36-8((4-methoxy-3-trifluoromethylphenyl)boronic acid)
• 301699-39-8(3,5-Dimethyl-4-methoxyphenylboronic acid)
• 175883-62-2(4-Methoxy-3-methylphenylboronic acid)
• 917757-15-4(3-Methoxy-4-methylphenylboronic acid)
• 849062-06-2((3-((4-(Trifluoromethoxy)phenoxy)methyl)phenyl)boronic acid)